

NEWS RELEASE

BIOSENSORS SIGNS MOU WITH P.T. KIMIA FARMA, A STATE-OWNED,
PUBLICLY-LISTED HEALTHCARE COMPANY IN INDONESIA

Singapore, 16, Aug 2007 – Biosensors International Group, Ltd. (Bloomberg: BIG SP, “Company” or “Biosensors”), today announced that its Singapore subsidiary, Biosensors Interventional Pte Ltd has entered into a Memorandum of Understanding (“MOU”) with PT Kimia Farma, a state-owned, publicly-listed healthcare company in the Republic of Indonesia, to localize the manufacturing of Biosensors’ coronary bare-metal stents and accessory products with the aim of supplying these as choice coronary products to local government hospitals in Indonesia.

The collaboration with PT Kimia Farma heralds one of Biosensors’ strategies to further penetrate the interventional cardiology market in Indonesia, the world’s fourth most populous country with a population of about 230 million.

PT Kimia Farma is a leading healthcare company in Indonesia with more than 187 years of history. As a state-owned company, Kimia Farma pioneered the Indonesian pharmaceutical industry and was merged with several state pharmaceutical companies in 1969. In 2001, it was listed on the Jakarta and Surabaya Stock Exchange and quickly became a leading healthcare company in Indonesia and contributed to the growth and development of Indonesia and its healthcare system.

Mr. Gunawan, President of Kimia Farma said, “The number of Indonesian patients requiring coronary care is on the rise. There are more than 1,000 hospitals in Indonesia and close to 40 percent are government hospitals that continue to be the huge catchments for patients who need coronary stents but cannot afford them. We are very delighted that together with Biosensors, we can market Biosensors’ S-Stent™, a high quality coronary bare-metal stent, to the government hospital and have these hospitals adopt the S-Stent as the stent-of-choice.”

Biosensors has been marketing its S-Stent in Europe since 2001 when it obtained the CE Mark regulatory approval for its commercialization. In October 2006, the S-Stent was also approved for commercialization in Japan by the Japanese regulatory body, Ministry of Health, Labor & Welfare. The S-Stent has demonstrated a low restenosis rate of 10.9 percent compared to a high of 35 percent in other bare-metal stents. Restenosis is the re-narrowing of the arteries which often occurs following implantation of coronary stents.

Mr. Chua Kee Lock, President of Biosensors said, “The market in Indonesia is potentially large and for a start, we anticipate this collaboration to increase the annual sales of our S-Stent. While the short term revenue increase will likely be less than 10 percent of our current revenue, our alliance with Kimia Farma will enable us to enlarge our participation in the growing Indonesian market and work closely with the government and employ our innovative medical products to address the healthcare needs of patients in Indonesia. We believe that this relationship will help springboard other business relationships in the future, including the commercialization of our BioMatrix™ drug-eluting stent.”

End of Release

Media & Investor Relations

Singapore

Mr. Loh Chee Mun
Senior Vice President
Tel: (65) 62135708
Email: cm.loh@biosensors.com

United States

Allen&CaronInc
Mr. Matt Clawson
Executive Vice President, Investor Relations
Tel: (1) 949 474 4300
Email: matt@allencaron.com

About Biosensors International Group, Ltd

Biosensors develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. Biosensors is well-positioned to emerge as a leader in drug-eluting stents, an evolving therapy that is rapidly gaining market share from traditional therapies such as bare-metal stenting and open-heart surgery. Biosensors has internally developed technology to address each component of a drug-eluting stent system, including a stent, a stent delivery catheter, a biodegradable polymer and a proprietary anti-restenosis drug. It is pursuing three separate drug-eluting stent programs, BioMatrix[®], Axxion[™], and BioMatrix[®] Freedom[™], a polymer-free drug-eluting stent, and has licensed aspects of its drug-eluting stent technology to four companies.

About PT Kimia Farma

Kimia Farma pioneered the Indonesian pharmaceutical industry. Supported by many years of experience, the company has grown rapidly to be an integrated health service company in Indonesia and plays an important role in the growth and development of the nation and its people. Since 2004, Kimia Farma shifted its paradigm resulting in changing the company’s business from a pharmaceutical company to a healthcare company. The new paradigm anticipates emerging awareness of the society to focus on preventing and managing health as opposed to curing illnesses and managing diseases. Therefore, Kimia Farma has been developing new business segments that include clinical laboratories and health clinics. As an integrated health service company, Kimia Farma has expertise in marketing, and through its distribution subsidiary company, it owns 41 distribution branches and has 21,364 outlets across Indonesia. Kimia Farma also manages retail business activities through the operations of the company’s owned pharmacy as well as cooperation operated pharmacy currently totaling 330. It also has a total of 25 clinical laboratories and 34 health clinics around Indonesia. These business segments are managed by the company’s head office.

Forward Looking Statements

Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words. All forward-looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.